@jmull14 asks, "What are your thoughts on PPHM? Appreciate your insight. Keep up the good work." Outside of day traders playing for pocket change, I see no reason to believe Peregrine Pharmaceuticals (PPHM) has a viable future. The cancer drug bavituximab has been thoroughly discredited and no amount of data outside the most perfectly conducted phase III study will ever convince anyone otherwise. I was amused to see Peregrine using its At-The-Market (ATM) equity facility to raise another $14 million over the past three weeks. Legal liability, anyone? That's just more sneaky, stealth dilution on the part of Peregrine's management team, but then given its shoddy track record when it comes to fiscal transparency, I shouldn't be surprised.
PLN mocks, "Nice job pumping Sarepta, you idiot." I'm a stock pumper now? Make up your mind. I can't be a stock pumper and a basher at the same time. I realize that traders are discomfited by Sarepta's fall from $44 to $24 since the beginning of October. The stock's rise from $4 to $44 (or even $24) is more impressive and noteworthy to me. Count me worried if Sarepta falls back to single digits, but not much before then. The additional eteplirsen data presented at the World Muscle Society meeting on Oct. 3 bolstered the Sarepta bull case. Argue all you want about the small patient numbers and bio-statistics, eteplirsen is producing functional dystrophin in DMD kids and that's helping these kids walk further. There is no placebo effect that can explain away these facts. I'm a Sarepta bull but not naive. The company's considerable challenge now is to convince FDA to consider eteplirsen for accelerated approval. Luckily, the company will be assisted by new federal regulations aimed at speeding approval of drugs for rare diseases. Advocates and parents of DMD kids are already organizing to lobby FDA on eteplirsen's behalf. They, more than anyone, know what's at stake here. So, Sarepta's recent fall looks to me like a second chance to pick up the stock at a reasonable valuation. If Synageva Biopharma (GEVA) can sport a $1.2 billion market cap for an orphan drug with nine patients worth of phase I/II data, then Sarepta, with data from 12 patients in a well-run phase II study treating DMD patients for 48 weeks is certainly worth a lot more than $500 million.
@Chasingthealpha asks, "Does $GILD take it on the chin post-AASLD when analysts/funds realize $ABT is a real threat?" The answer depends on the cure rate (SVR) in treatment-naive genotype 1 patients posted by Gilead Sciences' (GILD - Get Report) GS-7977/GS-5885 combination hepatitis C therapy. Abbott (ABT) has set the SVR bar high at 96% (possibly as high as 99%), which doesn't leave Gilead much room for error. Gilead needs to bring a 90%-plus cure rate to the table if it wants to compete with Abbott. Gilead's dosing convenience (two drugs, co-formulated into a single pill) is an advantage over Abbott's multi-drug, twice-daily regimen but only if the respective cure rates are within shouting distance of each other. On Monday, ISI Group analyst Mark Schoenebaum emailed results from his latest sentiment poll showing buyside investors predict, on average, an 85% SVR rate for Gilead's '7977/'5885 combo. Gilead is the best-performing large-cap biotech stock this year by a wide margin and its HIV franchise appears to be re-gaining momentum, so the company might have enough Wall Street support built up to under-deliver in Hep C and emerge unscathed. Future Hep C drug sales are forecast to top $15 billion so there's enough market share for Gilead, Abbott and other players to capture. -- Reported by Adam Feuerstein in Boston. Follow @AdamFeuerstein